RGNX
REGENXBIO Inc.
NASDAQ · USHealthcareBiotechnology
$10.32+4.35%
Price as of Jul 20, 2026
RGNX profitability
REGENXBIO Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -0.1%
- EBITDA margin
- -261.2%
- EBIT margin
- -292.3%
- Net margin
- -330.2%
- Free cash flow margin
- -269.2%
Returns
- Return on equity
- -1375.6%
- Return on assets
- -84.8%
- Return on invested capital
- -278.6%
- Asset turnover
- 0.22x
Cash efficiency
- Cash from operations
- -$233.8M
- Cash per share
- $2.91
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.